ACE and hepatocellular carcinoma: Conversely, Zhang and coworkers reported that ACE inhibitors may compromise the effects of anti-angiogenic drugs in HCC mouse models (120), thus supporting the necessity for a rigorous monitoring and control of hypertension in MASLD-HCC patients to optimize treatment efficacy and outcomes.